Health In Tech (HIT) Q4 2025 earnings review
Record Year Overshadowed by Sudden Q4 Contractions
Health In Tech delivered a massive 71% YoY revenue increase for FY25, heavily validating its AI-driven underwriting and channel partner expansion model. However, Q4 flashed glaring red warning signs. Total revenue decelerated sequentially for the second straight quarter, dropping to $7.5M. More alarmingly, billed enrolled employees reversed trajectory, shrinking from over 25,000 in Q3 to 22,515 by year-end. This contraction wiped out profitability, plunging Q4 net income back into negative territory. Management remains highly optimistic, aggressively targeting $45M-$50M in FY26 revenue via large-group market expansion, but they must first explain Q4's fundamental disconnect between stated momentum and actual performance.
🐂 Bull Case
Management expects FY26 revenue of $45M to $50M, implying roughly 35% to 50% YoY growth. The rollout of the large-group platform (150+ employees) vastly expands the total addressable market.
HIT’s AI platform cuts traditional underwriting cycles from months to minutes. This dominant workflow advantage helped expand the distribution network by 34% YoY to 858 partners.
🐻 Bear Case
Despite a massive YoY increase, billed enrolled employees dropped sequentially from 25,248 in Q3 to 22,515 in Q4. This signals serious Q4 churn or pipeline execution failures during a supposedly busy renewal period.
Cost of revenues tripled YoY in Q4 to $3.38M. Consequently, Q4 gross margins collapsed to 55.0% from 77.4% a year ago, dragging Adjusted EBITDA down 34% YoY.
⚖️ Verdict: ⚪
Neutral. The company operates in a massive TAM and possesses disruptive technology, but sequential declines in revenue, margins, and user base completely contradict the management's bullish narrative. Execution risk is extremely high.
Key Themes
Hidden Customer Churn and Revenue Reversal
While management touted a 23% YoY increase in billed enrolled employees, tracking sequential data reveals a severe reversal. The user base peaked in Q3 at 25,248 and fell by roughly 2,700 lives in Q4. Consequently, Q4 revenue ($7.5M) decelerated significantly from Q3 ($8.5M) and Q2 ($9.3M). This directly contradicts prior management claims that Q4 and Q1 are the strongest periods due to health plan renewal cycles.
Severe Margin Compression
Profitability took a massive hit in Q4. Cost of revenues surged over 200% YoY to $3.38M, slashing GAAP gross margins to a low of 55.0% (down from 77.4% in 24Q4). This toxic combination of falling sequential sales and rising delivery costs pushed the company back into a net loss of $0.3M and shrank Adjusted EBITDA to just $0.3M.
Expanding to Mid-Sized Employers
The successful deployment of the enhanced eDIYBS platform marks a critical shift upmarket. By automating data ingestion for groups of 150+ employees, HIT reduces underwriting cycles from up to three months down to days. This expands the company's TAM far beyond its legacy base of small businesses.
Productizing Stop-Loss to Accelerate Sales
In January 2026, the company launched over 100 pre-configured stop-loss programs. By moving away from purely customized, one-off underwriting toward standardized "execution-ready" agency programs, HIT is deliberately shortening sales cycles and improving conversion visibility.
Capitalizing on Legacy Carrier Rate Hikes
Traditional ACA carriers demanding annual rate increases of 20-30% create a powerful macro tailwind for HIT. To combat this volatility, HIT is currently testing a 3-Year Rate Stabilization program to provide multi-year price predictability, giving broker partners a massive differentiator to attract and retain clients.
High Run-Rate of Public Company Costs
General and administrative expenses remain highly elevated, reaching $3.18M in Q4 (42% of revenue). Management has previously attributed this to public company costs (D&O insurance, audits, IR). Investors must monitor if the company can grow out of this heavy fixed-cost base or if it will permanently impair operating margins.
Other KPIs
Accelerating YoY. Up roughly 162% from $2.47M in 24Q4. Fee-based revenues now make up 86% of total revenue, highlighting the successful strategic shift away from basic underwriting modeling toward higher-value program management.
Accelerating. Despite net income being only $1.27M, cash flow from operations grew 44% YoY, driven heavily by an increase in accounts payable and deferred revenue lines. However, $3.18M was used to capitalize software development, effectively resulting in breakeven free cash flow.
Stable YoY growth (+34%) but sequentially flat. The partner count increased by only 9 partners compared to Q3 2025 (849 partners). The rapid distribution expansion seen in early 2025 appears to be cooling off, forcing the company to rely more on deeper penetration within its existing broker base.
Guidance
Decelerating growth rate. The midpoint of $47.5M implies a 42.6% YoY growth, down from the massive 71% growth achieved in FY25. Given the sequential contraction witnessed in Q4 2025, hitting this aggressive target relies entirely on the rapid adoption of the new large-group and pre-configured stop-loss products.
Key Questions
Unexplained Q4 Contractions
Despite Q4 typically being a strong season for policy renewals, billed enrolled employees dropped by roughly 2,700 lives sequentially and revenue contracted for the second straight quarter. What drove this severe churn, and how does it square with your aggressive FY26 growth guidance?
Margin Degradation
Cost of revenues surged nearly 205% year-over-year in Q4, crushing gross margins to 55%. What structural changes in delivery or platform hosting drove this spike, and should investors view 55% as the new baseline moving forward?
Software Capitalization Impact
In FY25, you capitalized $3.18 million in software development, artificially boosting GAAP net income. Now that the eDIYBS mid-market platform and pre-configured stop-loss plans are launched, will capitalized R&D normalize, and how will the associated amortization drag on FY26 earnings?